EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening

Christina Rabe, Tobias Bittner, Alexander Jethwa, Ivonne Suridjan, Ekaterina Manuilova, Michel Friesenhahn, Erik Stomrud, Henrik Zetterberg, Kaj Blennow, Oskar Hansson, Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study

Alzheimer's & Dementia · 2023-04 · 19 (4) · 1393-1402

DOI: 10.1002/alz.12801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 23.09.2022. Verfasst von Christina Rabe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloidosis. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Further evidence is needed to support the use of plasma amyloid β (Aβ) biomarkers as Alzheimer's disease prescreening tools. This study evaluated the clinical performance and robustness of plasma Aβ 42 /Aβ 40 for amyloid positivity prescreening.

Methods

Data were collected from 333 BioFINDER and 121 Alzheimer's Disease Neuroimaging Initiative study participants. Risk and predictive values versus percentile of plasma Aβ 42 /Aβ 40 evaluated the actionability of plasma Aβ 42 /Aβ 40 , and simulations modeled the impact of potential uncertainties and biases. Amyloid PET was the brain amyloidosis reference standard.

Results

Elecsys plasma Aβ 42 /Aβ 40 could potentially rule out amyloid pathology in populations with low‐to‐moderate amyloid positivity prevalence. However, simulations showed small measurement or pre‐analytical errors in Aβ 42 and/or Aβ 40 cause misclassifications, impacting sensitivity or specificity. The minor fold change between amyloid PET positive and negative cases explains the biomarkers low robustness.

Discussion

Implementing plasma Aβ 42 /Aβ 40 for routine clinical use may pose significant challenges, with misclassification risks. Highlights Plasma Aβ 42 /Aβ 40 ruled out amyloid PET positivity in a setting of low amyloid‐positive prevalence. Including (pre‐) analytical errors or measurement biases caused misclassifications. Plasma Aβ 42 /Aβ 40 had a low inherent dynamic range, independent of analytical method. Other blood biomarkers may be easier to implement as robust prescreening tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloidosisHumansAmyloid beta-PeptidesBrainBiomarkersAmyloidPeptide Fragments

Stichwörter der Autor:innen

Alzheimer's diseaseamyloidbiomarkersblood biomarkersprescreening

Substanzen

Amyloid beta-PeptidesBiomarkersAmyloidPeptide Fragments

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, California, USA.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Roche Diagnostics GmbH, Mannheim, Germany.
  • Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
  • Memory Clinic, Skåne University Hospital, Malmö, Sweden.

Zitieren

APA

Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., & Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study (2023). Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening. Alzheimer's & Dementia, 19(4), 1393-1402. https://doi.org/10.1002/alz.12801

Vancouver

Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M, et al. Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening. Alzheimer's & Dementia. 2023;19(4):1393-1402. doi:10.1002/alz.12801

BibTeX
@article{Rabe2023,
  author = {Rabe, Christina and Bittner, Tobias and Jethwa, Alexander and Suridjan, Ivonne and Manuilova, Ekaterina and Friesenhahn, Michel and Stomrud, Erik and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar and Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study, Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study},
  title = {Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {4},
  pages = {1393--1402},
  doi = {10.1002/alz.12801}
}
Kostenlos starten →